Amarin's worth is based on: Patented Products with Superior proven performance & Management team.
In my years of being in business-- I have learnt Management Team is very important. You can have great products--but they can deliver fair results under fair mgmt.team.
Vertex is a recent example.
Does Amarin have great product? I think so.
Does Amarin have great management team? I think so--especially for hiring Paul Huff by Joe Zakrzewski.
Amarin has hired top talent in R&D,legal affairs,external attorneys,top patent law firm.
Look at 889 patent--- It is now going to be issued on Oct.23,2012. Normally it takes one to two years.
When 889 was rejected,Joe cited 25 patents. I did not believe him.But now I see 7 of them close to being issued.My confidence--that Amarin can protect its territory until 2030 looks better.
Having said that: Remember Competition is a MOVING TARGET.
Merck had patents for ZOCOR---they lived in dream world that they have protection for many years and they pooh-poohed Lipitor's patents. WELL THEY WERE WRONG.
Even CRESTOR by AZN surprised Pfizer and others-Lipitor sales peaked at 10 bill.$ as Crestor took away 6.5 billion$ from Statin market.
WILL SOMEONE come up with a BETTER Product that lowers Cholestrols and Trigylcerides and other Heart profile? Many are working on it--but results are so far not very promising.Sanofi has a better product that may be available in 2016.But that is in Statin family also.
I think-- buyout of Amarin is going on. But the problem is BID & ASK.
In April,2011--Bid was 15$ -Joe wanted 30$. (reported by Bloomberg with Joe's comment in June,2011).
Now bid is in low 20's-- Joe wants 35$/Share.
Goldman Sachs or Lazard can bring the parties closer as GS did with Amylin in July.2012.
If not,then we may have to wait till 2014.
Mtd, I agree with Akanz and you're both great assets to the board.
I don't think AMRN or their suitor(s), will sit on their hands. Even the analysts are greatly interested in the prospect of a combo drug. At the last cc, one analyst went so far as to question Joe Z further about the statin-Vascepa study to be announced later this year. Said analyst asked if it would be a "spray-coated" pill. Joe remained coy saying that for competitive reasons he wouldn't give out such details at this time.
Btw with all of the new and pending patents that AMRN has filed, do any of the ones that have found their way onto Public Pair claim a method of spray coating a statin agent on a capsule containing purified EPA?